Cover - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 25, 2026 |
Jun. 30, 2025 |
|
| Document Information [Line Items] | |||
| Document Type | 10-K | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Annual Report | true | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Transition Report | false | ||
| Entity File Number | 001-35890 | ||
| Entity Registrant Name | Tempest Therapeutics, Inc. | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 45-1472564 | ||
| Entity Address, Address Line One | 2000 Sierra Point Parkway | ||
| Entity Address, Address Line Two | Suite 400 | ||
| Entity Address, City or Town | Brisbane | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94005 | ||
| City Area Code | (415) | ||
| Local Phone Number | 798-8589 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 30.1 | ||
| Entity Common Stock, Shares Outstanding | 14,344,034 | ||
| Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE
None. |
||
| Entity Central Index Key | 0001544227 | ||
| Amendment Flag | false | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| ICFR Auditor Attestation Flag | false | ||
| Auditor Firm ID | 42 | ||
| Auditor Name | Ernst & Young LLP | ||
| Auditor Location | Chicago, Illinois | ||
| Auditor Opinion | Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Tempest Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. |
||
| Common Stock | |||
| Document Information [Line Items] | |||
| Title of 12(b) Security | Common Stock, $0.001 par value | ||
| Trading Symbol | TPST | ||
| Security Exchange Name | NASDAQ | ||
| Series A Junior Participating Preferred Purchase Rights | |||
| Document Information [Line Items] | |||
| Title of 12(b) Security | Series A Junior Participating Preferred Purchase Rights | ||
| No Trading Symbol Flag | true | ||
| Security Exchange Name | NASDAQ |